Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer (Q39001792)

8 September 2017

Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer (English)

1 reference

8 September 2017

Andrea Z Lai

1

1 reference

8 September 2017

Sean Cory

2

1 reference

8 September 2017

Hong Zhao

3

1 reference

8 September 2017

Mathieu Gigoux

4

1 reference

8 September 2017

Anie Monast

5

1 reference

8 September 2017

Marie-Christine Guiot

6

1 reference

8 September 2017

Sidong Huang

7

1 reference

8 September 2017

Ali Tofigh

8

1 reference

8 September 2017

Crista Thompson

9

1 reference

8 September 2017

Monica Naujokas

10

1 reference

8 September 2017

Victoria A Marcus

11

1 reference

8 September 2017

Nicholas Bertos

12

1 reference

8 September 2017

Bita Sehat

13

1 reference

8 September 2017

Rushika M Perera

14

1 reference

8 September 2017

Emily S Bell

15

1 reference

8 September 2017

Brent D G Page

16

1 reference

8 September 2017

Patrick T Gunning

17

1 reference

8 September 2017

Lorenzo E Ferri

18

1 reference

8 September 2017

Michael Hallett

19

1 reference

8 September 2017

Morag Park

20

1 reference

8 September 2017

22 April 2014

1 reference

8 September 2017

1 reference

8 September 2017

7

1 reference

8 September 2017

322

1 reference

8 September 2017

ra38

1 reference

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

8 September 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Amplification of the MET gene in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Progress in cancer therapy targeting c-Met signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Crosstalk in Met receptor oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Down-regulation of MET, the receptor for hepatocyte growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Somatic mutations lead to an oncogenic deletion of met in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

MET: a promising anticancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Molecular targeted agents for gastric and gastroesophageal junction cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Coordinated regulation of life and death by RB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

A module of negative feedback regulators defines growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Essential role of Gab1 for signaling by the c-Met receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

How to make tubes: signaling by the Met receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Akt, FoxO and regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Met receptor tyrosine kinase: enhanced signaling through adapter proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Stat3 regulates genes common to both wound healing and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

A user's guide to the encyclopedia of DNA elements (ENCODE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Emerging roles of E2Fs in cancer: an exit from cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Dual-specificity phosphatases: critical regulators with diverse cellular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

The role of Gab family scaffolding adapter proteins in the signal transduction of cytokine and growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

From Tpr-Met to Met, tumorigenesis and tubes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Crk adapter proteins promote an epithelial-mesenchymal-like transition and are required for HGF-mediated cell spreading and breakdown of epithelial adherens junctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

ERK1/2 MAP kinases: structure, function, and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

MEK1/2 dual-specificity protein kinases: structure and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Signaling networks assembled by oncogenic EGFR and c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Negative feedback and adaptive resistance to the targeted therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

SOCS proteins: negative regulators of cytokine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Discovery of a novel B-Raf fusion protein related to c-Met drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

Only a Subset of Met-Activated Pathways Are Required to Sustain Oncogene Addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2004839

10.1126/SCISIGNAL.2004839

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference